New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Check below for free stories on GOOG;EMC;VMW;INTC;GILD;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
April 23, 2014
16:00 EDTGILDOptions Update; April 23, 2014
iPath S&P 500 VIX Short-Term Futures up 12c to 41.01. Option volume leaders: AAPL C GILD GOOG TSLA ZNGA TWTR FB according to Track Data.
12:57 EDTVMW, EMCEMC profit cycle bottomed in Q1, says Cantor
Subscribe for More Information
12:05 EDTGILDStocks with call strike movement; DAL GILD
Subscribe for More Information
12:01 EDTEMC, VMWVMware sinks after enterprise licenses, outlook may have disappointed
Shares of VMware (VMW), a provider of virtualization infrastructure solutions, are among today's losers despite the company having reported results that beat the consensus forecast. Several analysts contended that the company reaffirming its full-year outlook and reporting lower than expected enterprise license agreements as a percentage of bookings may have disappointed investors. WHAT'S NEW: Last night, VMware reported first quarter earnings per share of 80c and revenue of $1.36B, compared to expectations of 79c and $1.35B, respectively. VMware said Q1 license and total bookings growth was less than 10% compared to the prior year. VMware forecast Q2 revenue of $1.43B-$1.47B, compared to consensus of $1.44B. The company reaffirmed its fiscal 2014 revenue view of $5.94B-$6.1B, versus consensus of $6.03B. It also expects FY14 non-GAAP operating margin of approximately 31%. FY14 license revenue was expected to be $2.55B-$2.63B, up 12%-16% from the prior year. ANALYST REACTION: This morning, research firms Oppenheimer, Pacific Crest, and Raymond James all recommended buying VMware on any weakness. Pacific Crest said lower than expected enterprise license agreements as a percentage of bookings and weaker overall bookings growth disappointed the Street. Another firm, Janney Capital, said it believes investors may be slightly disappointed that VMware reiterated its prior guidance after its Q1 EPS slightly beat expectations. However, the firm believes the stock's valuation offers a good entry point and reiterates its Buy rating on the name. PRICE ACTION: In late morning trading, VMware fell $9.15, or 8.7%, to $96 on heavy trading volume. Despite today's pull back, the stock is up approximately 27% over the past twelve months. ANOTHER TO WATCH: EMC (EMC), which is the majority owner of VMware, reported earnings and revenue that were roughly in-line with expectations and raised its quarterly dividend. However, EMC lowered its 2014 EPS outlook to $1.90 from $1.95, which was below the consensus $1.94 forecast, and its shares were down 3% to $25.94 near noon.
12:00 EDTVMWVMware falls 8.8%
Subscribe for More Information
11:34 EDTGILDGilead climbs after hep C drug sales top $2B in Q1
Shares of drug maker Gilead (GILD) are surging after the company reported better than expected first quarter results and noted that its Hepatitis C drug had generated sales of $2.27B during the quarter. WHAT'S NEW: Gilead reported Q1 earnings per share of $1.48, versus analysts' consensus estimate of 89c. The company's revenue came in at $5B, versus the consensus forecast of $3.9B. Gilead obtained $2.27B of revenue from its Hepatitis C treatment, Solvaldi, which was launched in December. There was strong demand for Sovaldi from U.S. hepatitis C patients, Gilead Executive VP, Commercial Operations Paul Carter said on the company's results conference call. ANALYST REACTION: A number of analysts reacted positively to Gilead results. In a note to investors earlier today, Robert W. Baird analyst Brian Skorney wrote that last quarter, Sovaldi tied Lipitor for the highest U.S. quarterly sales of any drug in history. In light of Sovaldi's performance, analysts' 2014 and 2015 estimates for the company clearly must increase, the analyst contended. Even if Sovaldi's sales are cut in half from their peak levels in 2015-2017, the stock should still rise, Skorney wrote. He kept a $103 price target and Outperform rating on the stock. Also upbeat on Gilead was Wells Fargo. The launch of Sovaldi was "as good as it gets," and Gilead's results were "outstanding," the firm contended. It kept an $87-$91 price target and Outperform rating on the stock. OTHERS TO WATCH: AbbVie (ABBV) is also developing a treatment for hepatitis C. PRICE ACTION: In morning trading, Gilead gained $2.11, or 2.9%, to $74.97, while AbbVie shares were down 0.6% to $49.71.
10:00 EDTVMWVMware falls 9%
VMware is down 9%, or $9.48, to $95.67
09:55 EDTVMWVMware weakness a buying opportunity, says Raymond James
Shares are Strong Buy rated with a $125 price target.
09:36 EDTVMWVMware drops following results, levels to watch
Shares initially traded higher in the extended session following results but have gapped down this morning. At the current price of $95.49, next support is at $93.07 and then at $91.72. Resistance is at $96.69.
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD NFLX TSLA VZ MU WFM AMGN
09:16 EDTVMW, GILDOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTVMWVMware falls 5.4%
Subscribe for More Information
08:40 EDTGILDGilead's Sovaldi durability questions remain but upside justified, says Baird
Baird noted Gilead's Sovaldi sales durability remains a question past 2015 but even if sales were cut in half there is still justification for upside to shares. The firm sees the Congressional letter questioning Sovaldi's price as in the rear view mirror and expects margin improvements and Sovaldi sales to continue to become a bigger portion of Gilead's revenue base in coming quarters. Shares are Outperform rated with a $103 price target.
08:34 EDTGOOGGoogle and SunPower partner to finance $250M in residential solar lease projects
Subscribe for More Information
08:27 EDTVMWVMware backing guidance may be slightly disappointing, says Janney Capital
Subscribe for More Information
08:10 EDTGOOGGoogle took on some Samsung liability in fight with Apple, Re/code says
Subscribe for More Information
08:04 EDTVMWVMware should be bought on any weakness, says Pacific Crest
Subscribe for More Information
07:55 EDTGILDGilead Q1 results 'outstanding,' says Wells Fargo
After Gilead reported stronger than expected Q1 results, Wells Fargo thinks that the company's Sovaldi sales likely exceeded most Street estimates. The firm thinks the strong Sovaldi launch bodes well for the drug's long-term outlook. It keeps an $87-$91 price target and Outperform rating on the stock.
07:41 EDTVMWVMware should be bought on any weakness, says Oppenheimer
Subscribe for More Information
07:12 EDTEMCEMC lowers 2014 EPS outlook to $1.90 from $1.95, consensus $1.94
Sees 2014 revenue $24.575B, consensus $24.51B. EMC expects to repurchase an aggregate of $2B of the company's common stock in 2014. The company said, "While planned business practice changes had a negative impact on year-over-year revenue and EPS growth in the quarter, we are very confident we are on the right track with our Federation model and technologies. With our strong foothold in Second Platform environments and some of the most exciting IT assets in the industry helping us propel customers to the Third Platform of IT, EMC is well positioned to meet our stated 2014 targets."
07:09 EDTEMCEMC raises quarterly dividend to 11.5c from 10c
EMC said its board approved a 15% increase in the quarterly cash dividend paid to shareholders. The first increased dividend of 11.5c per share of common stock will be paid on July 23, to shareholders of record as of the close of business on July 1.
07:09 EDTEMCEMC reports Q1 EPS 35c, consensus 35c
Reports Q1 revenue $5.48B, consensus $5.43B.
07:09 EDTEMCEMC reports Q1 EPS 35c, consensus 35c
Subscribe for More Information
06:28 EDTGOOGGoogle ads to link inside mobile apps
Google says it will allow advertisers to direct smartphone users directly to apps installed on their devices. Reference Link
06:24 EDTINTCIntel to launch Bay Trail-Entry to tap entry-level tablet market, DigiTimes says
Subscribe for More Information
05:34 EDTGILDGilead 'officially a value stock' after Q1 results, says Piper Jaffray
Piper Jaffray believes Gilead is "officially a value stock" following the company's Q1 results, which the firm calls "one of the most impressive beats in biopharma history." Piper thinks the stock will appeal to value investors and it reiterates an Overweight rating on the name while raising its price target to $106 from $105.
April 22, 2014
19:09 EDTVMW, GILDOn The Fly: After Hours Movers
Subscribe for More Information
17:40 EDTVMWVMware reaffirms FY14 revenue view $5.94B-$6.1B, consensus $6.03B
Subscribe for More Information
17:32 EDTVMWVMware says Q1 license and total bookings growth of less than 10% YoY
17:29 EDTVMWVMware sees FY14 license revenue $2.55B-$2.63B, up 12%-16% YoY
Subscribe for More Information
17:27 EDTVMWVMware sees Q2 revenue $1.43B-$1.47B, consensus $1.44B
Guidance from Q1 earnings conference call.
17:15 EDTVMWVMware says Q2 off to a solid start, sees Q2 bookings accelerating from Q1
Subscribe for More Information
16:33 EDTGILDOn The Fly: Closing Wrap
Subscribe for More Information
16:30 EDTGILDGilead resumes trading, shares up 4% to $76.00 after Q1 beat
Subscribe for More Information
16:07 EDTVMWVMware trades higher after results, first look
Subscribe for More Information
16:05 EDTGILDGilead reports Q1 EPS $1.48, consensus 89c
Reports Q1 revenue $5.0B, consensus $3.92B. Product sales increased to $4.87B. Antiviral product sales increased to $4.51G for Q1, up from $2.06B for Q1 of 2013 largely due to sales of Sovaldi.
16:04 EDTGILDGilead reiterates 2014 net product sales outlook $11.3B-$11.5B
Subscribe for More Information
16:04 EDTGOOGOptions Update; April 22, 2014
Subscribe for More Information
16:01 EDTVMWVMware reports Q1 EPS 80c, consensus 79c
Subscribe for More Information
16:00 EDTGILDGilead trading halted, pending news
Subscribe for More Information
15:32 EDTEMCNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Procter & Gamble (PG), consensus $1.02; Boeing (BA), consensus $1.56; Biogen Idec (BIIB), consensus $2.56; Dow Chemical (DOW), consensus 71c; EMC Corporation (EMC), consensus 35c; Thermo Fisher (TMO), consensus $1.40; Praxair (PX), consensus $1.51; General Dynamics (GD), consensus $1.64; Johnson Controls (JCI), consensus 65c; Norfolk Southern (NSC), consensus $1.15; Reynolds American (RAI), consensus 74c; Delta Air Lines (DAL), consensus 29c; Northrop Grumman (NOC), consensus $2.15; Air Products & Chemicals (APD), consensus $1.35; TD Ameritrade (AMTD), consensus 34c; Ingersoll-Rand (IR), consensus 26c; Dr Pepper Snapple (DPS), consensus 59c; Polaris Industries (PII), consensus $1.16; Ryder System (R), consensus 87c.
15:32 EDTGILD, VMWNotable companies reporting after market close
Subscribe for More Information
15:10 EDTEMCEarnings Preview: EMC shares up 6% since Q4 report
Subscribe for More Information
13:18 EDTGOOGOpera says Android overtook iOS in mobile ad traffic
Subscribe for More Information
13:07 EDTGOOGYouTube's head of product leaving company, Re/code reports
Subscribe for More Information
07:36 EDTGILDGilead weakness has created attractive entry point, says Stifel
Subscribe for More Information
06:37 EDTGOOGCompanies with cloud businesses worried about Aereo case, Re/code says
Subscribe for More Information
April 21, 2014
16:32 EDTGILDU.S. FDA accepts Gilead's NDA's for Cobicistat and Elvitegravir
Gilead Sciences announced that the U.S. FDA has accepted the company’s refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. The FDA has set target review dates under the Prescription Drug User Fee Act of October 3 for cobicistat and October 4 for elvitegravir. Gilead submitted NDAs for cobicistat and elvitegravir in June 2012. In April 2013, the company received Complete Response Letters from the FDA. In its communications, the agency stated that it could not approve the cobicistat and elvitegravir applications in their current forms, citing deficiencies in documentation and validation of certain quality testing procedures and methods that were observed during inspections. Gilead has worked with the FDA to address the questions raised in the Complete Response Letters. Cobicistat and elvitegravir are components of Gilead’s Stribild, a once-daily single tablet regimen for the treatment of HIV-1 infection. Stribild was approved in the United States in August 2012. Cobicistat is approved under the tradename Tybost and elvitegravir is approved under the tradename Vitekta in Europe, Canada and Australia.
16:01 EDTGILDOptions Update; April 21, 2014
iPath S&P 500 VIX Short-Term Futures down 78c to 40.03. Option volume leaders: AAPL C GILD NFLX TSLA TWTR FB WLT according to Track Data.
14:24 EDTGILDCVS wants price competition to Gilead's hepatitis C drug, Bloomberg says
CVS said it may try to slow uptake of Gilead's new hepatitis C drug, which costs $1,000 per pill. Bloomberg cites an interview with CVS's CMO Troy Brennan.
13:41 EDTEMCEMC April weekly volatility elevated into Q1 and outlook
EMC April weekly call option implied volatility is at 38, May is at 22, June is at 21; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 23.
13:36 EDTGOOGGoogle wants to add encryption tools to Gmail, VentureBeat says
Subscribe for More Information
10:49 EDTGOOGOptions with decreasing implied volatility: SRPT NSR INFY CMG GOOG
Subscribe for More Information
10:20 EDTGILDGilead volatility increases into Q1 and outlook
Gilead April weekly call option implied volatility is at 65, May is at 40, June is at 34, August is at 33; compared to its 26-week average of 34 according to Track Data, suggesting large near term price movement into the expected release of Q1 result son April 22.
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:03 EDTVMWVMware volatility elevated into Q1 and revenue growth outlook
Subscribe for More Information
07:43 EDTINTCSMART Technologies announces share structure changes after board resignations
Subscribe for More Information
07:21 EDTGILDFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
06:48 EDTGOOGMicrosoft faces internal & external conflicts in three segments, DigiTimes says
Subscribe for More Information
06:45 EDTGOOGApple and Google compete to offer exclusive game apps, WSJ reports
Subscribe for More Information
06:41 EDTGOOGGoogle to partner with HTC for 8-inch Nexus, DigiTimes reports
Subscribe for More Information
06:37 EDTGOOGSquare discusses possible sale as losses widen, WSJ reports
Mobile-payments startup Square discussed a possible sale to several rivals as its losses widen, reports the Wall Street Journal, citing people familiar with the matter. Google (GOOG) discussed a possible acquisition of the company earlier this year, but it was not clear if the talks were continuing. Square also had discussions about a deal with Apple (AAPL) and eBay's (EBAY) PayPal. Reference Link
06:26 EDTGOOG, INTCCourt documents say Silicon Valley giants discussed hiring, WSJ says
Google (GOOG), Apple (AAPL), Intel (INTC) and Adobe (ADBE had colluded with one another to supress wages between 2005 and 2009, reports the Wall Street Journal, citing documents from an antitrust case. The companies had agreed not to poach each other's employees among other things. The companies had also tried to bring Facebook (FB) on board, but Facebook rejected the offer. Reference Link
April 19, 2014
20:17 EDTGOOGTwitter, Netflix, Amazon look pricey, Barron's says
Subscribe for More Information
April 17, 2014
18:27 EDTINTCAMD rallies after results top expectations
Shares of global semiconductor company Advanced Micro Devices (AMD) are advancing in the after-hours session after the company's first quarter results topped analysts' consensus estimates. WHAT'S NEW: After the bell, AMD reported Q1 adjusted earnings per share of 2c and revenue of $1.4B, compared to expectations of 0c and $1.34B, respectively. WHAT'S NOTABLE: The company forecast Q2 revenue flat to up 6%, compared to consensus of $1.36B. For fiscal 2014, the company expects to grow revenue on a year-over-year basis, and be profitable at the net income level. FY14 CapEx is expected to be approximately $120M. PRICE ACTION: In after-hours trading, AMD gained 23c, or about 6.2%, to $3.92. AMD's stock is up about 48% over the past twelve months, not including after-hours trading. OTHERS TO WATCH: Other companies in the semiconductor space space include Intel (INTC), Texas Instruments (TXN), and Micron Technology (MU).
16:45 EDTGOOGMarket swings to gains in holiday-shortened week
Subscribe for More Information
16:31 EDTGOOGOn The Fly: Closing Wrap
Subscribe for More Information
16:08 EDTFRXActavis, Forest Labs receive second request under Hart-Scott-Rodino from FTC
Subscribe for More Information
12:53 EDTGOOGOn The Fly: Midday Wrap
Subscribe for More Information
12:01 EDTINTCTSMC climbs after profit beats expectations
Subscribe for More Information
10:11 EDTGILD, GOOGHigh option volume stocks: CMG INFY GOOGL GOOG SNDK MAT YHOO BX KSU GILD
Subscribe for More Information
09:35 EDTGOOGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOGL GOOG NFLX TSLA AMZN GOLG NOV AA IBM
09:09 EDTGOOGGoogle price target lowered to $670 from $710 at RBC Capital
Subscribe for More Information
08:58 EDTGOOGOn The Fly: Pre-market movers
Subscribe for More Information
08:45 EDTGOOGThe Cato Institute to hold a discussion
Subscribe for More Information
08:18 EDTGOOGGoogle capex expansion positive for Finisar, Juniper, says Janney Capital
Subscribe for More Information
08:12 EDTGOOGGoogle price target lowered to $660 from $690 at BofA/Merrill
Subscribe for More Information
07:24 EDTGOOGFutures lower as earnings disappoint
U.S. equity futures are lower following disappointing earnings reports from tech giants IBM (IBM) and Google (GOOG). Earnings will be taking center stage for the next few weeks Meanwhile, investors will continue to analyze economic data. Expected to be released today are weekly jobless claims data and the natural gas inventory report.
06:51 EDTGOOGGoogle shares still compelling, says Cantor
Subscribe for More Information
05:56 EDTGOOGGoogle price target lowered to $625 from $665 at Deutsche Bank
Deutsche Bank lowered its price target for Google shares to $625 following the company's Q1 results but it continues to view the stock as a top idea. The firm views the results as in-line and it keeps a Buy rating on Google.
05:49 EDTGOOGGoogle price target raised to $735 from $725 at Credit Suisse
Credit Suisse raised its price target for Google shares to $735 and reiterates an Outperform rating on the stock following the company's Q1 results. Credit Suisse views the results as mixed, but says the most important takeaway was the positive inflection in the CPC decline rate.
April 16, 2014
18:55 EDTGOOGOn The Fly: After Hours Movers
Subscribe for More Information
17:57 EDTGOOGYahoo seeks default search status for Apple products, Re/code says
Subscribe for More Information
16:42 EDTGOOGGoogle says Moto G showed 'strong sales momentum' in emerging markets
Comment made on company's Q1 earnings webcast.
16:40 EDTGOOGOn The Fly: Closing Wrap
Stocks on Wall Street were higher after Fed Chair Janet Yellen struck a dovish tone in comments to the Economic Club of New York, which was in step with the minutes of the last FOMC meeting released last week. The Fed also released its latest Beige Book report, which indicated that economic activity increased in most regions after the severe winter weather that gripped much of the country to start the year had let up. Corporate earnings season continues to pick up steam, with Dow members IBM (IBM) and American Express (AXP), as well as Google (GOOG), reporting after the market close. ECONOMIC EVENTS: In the U.S., housing starts in March were up 2.8% from the prior month to a rate of 946K, versus expectations for an increase of 7%. Building permits were down 2.4% to a 990K rate, versus expectations for a decline of 0.4%. Industrial production rose 0.7% in March, which was ahead of the 0.5% forecast. The Fed's Beige Book report indicated that economic activity rebounded and strengthened in most regions over the last six week. In China, data showed its economy grew 7.4% in the first quarter from a year earlier, providing relief after recent signs that growth in the world's second largest economy has been slowing. COMPANY NEWS: Bank of America (BAC) fell 26c, or 1.59%, to $16.13 after the bank reported a first quarter loss of 5c per share, largely due to $6B in legal charges. Excluding the impact of this litigation expense, which was related to a previously announced settlement with the Federal Housing Finance Agency and other legacy mortgage-related matters, the banking major reported earnings that appeared to beat estimates... Yahoo (YHOO) gained $2.14, or 6.26%, to $36.35 after its quarterly report, with investors reacting most positively to the 66% year-over-year revenue growth reported by Chinese e-commerce company Alibaba, in which Yahoo holds a 24% stake. Yahoo's quarterly profit and revenue also beat expectations and the company's CEO Marissa Mayer said during its earnings webcast that the search giant's core business has moved from declining growth to stable to modest growth. MAJOR MOVERS: Among the notable gainers was CBS Outdoor (CBSO), which jumped $1.94, or 6.69%, to $30.96 after the IRS approved a plan for the company, which was just last week spun-off from its parent CBS (CBS), to convert into a real estate investment trust, or REIT. Other companies seeking REIT status, including Equinix (EQIX), Iron Mountain (IRM) and Lamar Advertising (LAMR), also rose following CBS' announcement. Also higher was drugmaker Zogenix (ZGNX), up 48c, or 20.51%, to $2.82 after confirming that a judge prevented a ban on sales of the company's Zohydro pain medication in Massachusetts. Among the noteworthy losers were U.S.-listed shares of Credit Suisse (CS), which fell 54c, or 1.7%, to $31.22 after the Swiss bank reported net income and revenue that fell when compared to the prior year. Also lower were Agnico Eagle Mines (AEM) and Yamana Gold (AUY) after agreeing to jointly acquire Osisko Mining. Angico shares fell $2.61, or 8.56%, to $27.88, while Yamana was down 36c, or 4.3%, to $8.02. INDEXES: The Dow was up 162.29, or 1.0%, to 16,424.85, the Nasdaq was up 52.06, or 1.29%, to 4,086.23, and the S&P 500 was up 19.33, or 1.05%, to 1,862.31.
16:06 EDTGOOGGoogle down more than 5% after missing on top and bottom lines
Subscribe for More Information
16:06 EDTGOOGGoogle says expects to continue to make 'significant capital expenditures'
Reports net cash provided by operating activities in Q1 totaled $4.39B, compared to $3.63B in the prior year period. In Q1, capital expenditures were $2.35B, the majority of which was for production equipment, data-center construction, and real estate purchases. Free cash flow in Q1 was $2.05B.
16:04 EDTGOOGGoogle reports Q1 average cost-per-click down 9%
Reports paid click up 26%. Reports traffic acquisition costs increased to $3.23B vs $2.96B for the prior year period.
16:03 EDTGOOGGoogle reports Q1 sites revenue up 21% to $10.47B
Reports Q1 network revenues up 4% to 3.4B.
16:03 EDTGOOGGoogle reports Q1 EPS $6.27, consensus $6.40
Subscribe for More Information
15:17 EDTGOOGNotable companies reporting after market close
Subscribe for More Information
14:54 EDTGOOGGoogle April 550 straddle priced for 5.3% move into Q1
Subscribe for More Information
10:51 EDTINTCOptions with decreasing implied volatility: DLLR FAST INTC
Subscribe for More Information
10:00 EDTINTCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTVMWVMware revenue, EPS should beat consensus, says Goldman
Subscribe for More Information
08:34 EDTGILDPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
08:20 EDTINTCIntel results, guidance were good, says Wells Fargo
Wells Fargo says that Intel's gross margin for its March quarter beat expectations, while the company guided for sequential revenue growth for its June quarter. The firm thinks the company is making some headway in penetrating the tablet market, and keeps an Outperform rating on the shares.
07:43 EDTINTCIntel price target raised to $35 from $32 at Jefferies
Subscribe for More Information
07:40 EDTGOOGGoogle Play Q1 downloads exceeded downloads from Apple store, App Annie says
Subscribe for More Information
07:30 EDTVMWVMware, Citrix may be threatened as OpenStack momentum builds, WSJ says
OpenStack supporters say the open-source operating system can bring the ease of use and agility offered by cloud-service vendors, while using a company's own server systems, and if it continues to be adopted OpenStack could pose a threat to companies to offer data center software and services including VMware (VMW), Citrix Systems (CTXS), Amazon.com (AMZN), Microsoft (MSFT) and others, said The Wall Street Journal. Reference Link
07:07 EDTGOOG, EMCAmazon, Google, Microsoft cut prices for cloud computing products, WSJ says
Subscribe for More Information
06:52 EDTGOOGSamsung objects to Apple's patent claims in $2B court battle, Bloomberg says
Subscribe for More Information
06:50 EDTGOOGGoogle could be working on smart contact lenses, Business Insider says
Subscribe for More Information
06:08 EDTGOOGGoogle seeking third-party developers for 'modular' project, WSJ reports
Subscribe for More Information
06:06 EDTINTCIntel price target raised to $30 from $28 at Deutsche Bank
Deutsche Bank raised its price target for Intel shares to $30 citing the company's "solid" Q1 results. The firm views Intel's second half guidance as conservative and keeps a Buy rating on the stock.
05:43 EDTINTCIntel downgraded to Neutral from Buy at B. Riley
Subscribe for More Information
April 15, 2014
18:58 EDTINTCOn The Fly: After Hours Movers
Subscribe for More Information
18:48 EDTINTCIntel CFO says plans to capitalize on the Internet of Things
Subscribe for More Information
17:51 EDTINTCIntel says 'squarely on track' to ship 40M tablet SOC's in 2014
Subscribe for More Information
16:30 EDTINTCIntel CFO sees gross margins 'in low 60's' in back half of 2014
Says making investments in mobile space. Says companies are buying new PC's to replace older installed base. Intel CFO Stacy Smith is speaking on CNBC.
16:15 EDTINTCIntel reports Q1 PC Client Group revenue $7.9B, down 8% sequentially
Subscribe for More Information
16:09 EDTINTCIntel rises to new 52-week high after results, first look
Subscribe for More Information
16:07 EDTINTCIntel CEO says saw solid growth in the data center in Q1
"In the first quarter we saw solid growth in the data center, signs of improvement in the PC business, and we shipped 5 million tablet processors, making strong progress on our goal of 40 million tablets for 2014," said Intel CEO Brian Krzanich. "Additionally, we demonstrated our further commitment to grow in the enterprise with a strategic technology and business collaboration with Cloudera, we introduced our second-generation LTE platform with CAT6 and other advanced features, and we shipped our first Quark products for the Internet of Things."
16:06 EDTINTCIntel sees Q2 gross margin 63%, plus or minus a couple of percentage points
Subscribe for More Information
16:05 EDTINTCIntel sees FY14 revenue approximately flat, consensus $53.15B
Sees FY14 gross margin 61%, plus or minus a few percentage points. Sees FY14 CapEx $11B, plus or minus $500M.
16:04 EDTINTCIntel reports Q1 gross margin 59.7%
Subscribe for More Information
16:03 EDTINTCIntel sees Q2 revenue $13B, plus or minus $500M, consensus $12.96B
Subscribe for More Information
16:02 EDTINTCIntel reports Q1 EPS 38c, consensus 37c
Reports Q1 revenue $12.8B, consensus $12.81B.
15:19 EDTINTCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Intel (INTC), consensus 37c; Yahoo (YHOO), consensus 37c; CSX (CSX), consensus 37c; Linear Technology (LLTC), consensus 48c; Wintrust Financial (WTFC), consensus 67c.
15:10 EDTINTCIntel April 26 straddle priced for 4% move into Q1
Subscribe for More Information
15:03 EDTGILDGilead treatment of chronic lymphocytic leukemia granted orphan status
The FDA granted the orphan designation on April 14, according to a post to the regulator's website. Reference Link
14:25 EDTINTCIntel April option elevated into Q1 and outlook
Intel April call option implied volatility is at 41, May is at 21, June and October is at 19; compared to its 26-week average of 21 according to Track Data, suggesting large near term price movement into the release of Q1 results today after the market close.
13:49 EDTINTCEarnings Preview: Analysts optimistic on Intel ahead of Q1 report
Subscribe for More Information
13:18 EDTGOOGDaniel Graf to join Twitter's product team
Daniel Graf, who led efforts on Google Maps (GOOG), is joining Twitter's (TWTR) product team, Graf announced in a tweet. Reference Link
12:45 EDTGOOGEarnings Preview: Google shares down 8% since last earnings report
Google (GOOG, GOOGL) is expected to report first quarter earnings after the market close on Wednesday, April 16 with a conference call scheduled for 4:30 pm ET. Google is a global technology company that focuses on Internet search, cloud computing, and advertising technologies. EXPECTATIONS: Analysts are looking for earnings per share of $6.39 on revenue of $15.52B. The consensus range is $5.83-$6.96 for EPS, and $14.94B-$16.12B for revenue, according to First Call. LAST QUARTER: Google reported Q4 EPS $12.01 against estimates of $12.26 on revenue of $16.86B against estimates of $16.75B. Google reported Q4 paid clicks up 31% and average cost-per-click decreased approximately 11%. The company also reported Q4 Sites revenue $10.55B and Q4 Network revenue $3.52B. NEWS: Google effectively split its stock with a dividend distribution of Class C shares, which began trading in early April. In the past quarter, the company reached a deal with a European Union after sending an improved commitments proposal in context of the ongoing antitrust investigation on online search and search advertising. Google also announced that it resolved the copyright litigation with Viacom (VIA, VIAB). The company announced partnerships and agreements with VMware (VMW), Cisco (CSCO), and OmniVision (OVTI) as well as acquisitions of SlickLogin, Titan Aerospace and parts of Green Throttle Games. STREET RESEARCH: Cantor said Google is being boosted by product listing ads, which are expected to increase the company's 2014 ad revenue by $1B. Atlantic Equities and Bernstein said Google's weakness provides a buying opportunity, citing strong year-over-year revenue growth at "core Google." Bernstein added predictions that Google Play, Computer and App Engine, and Apps for Enterprise and government will become multi-billion dollar businesses. Ahead of the Q1 earnings, Susquehanna said the results should beat expectations due to continued website growth, PLAs, and early benefits from Enhanced Campaigns and YouTube. PRICE ACTION: Google shares have dropped over 8% since the first day of trading following the company's Q4 report. In Tuesday midday trading ahead of Q1 report, Google shares are down a little over 2%.
08:39 EDTGOOGNetlist patent with LRDIMM claims confirmed in reexamination
Subscribe for More Information
08:20 EDTGOOGAeroVironment has limited comparability to Google acquisition, says CRT Capital
Subscribe for More Information
07:11 EDTGOOGLattice FPGAs selected by Google ATAP Group for Project Ara smartphone prototype
Subscribe for More Information
06:46 EDTGOOGGoogle price target raised to $700 from $650 at Jefferies
Jefferies raised its price target for Google shares to $700 ahead of the company's Q1 results on Wednesday and it keeps a Buy rating on the stock. The new price target reflects the sale of Motorola. Jefferies notes its survey indicates Google's traffic trends were solid in Q1.
06:38 EDTGOOGGoogle to use satellites to take photos, expand use of Internet, NY Times says
Google said that it would use Titan Aerospace's drone satellites to take photos of the Earth and connect people to the Internet, according to The New York Times. Google announced yesterday that it would buy Titan. Reference Link
06:02 EDTGOOGGoogle Glass goes on sale to U.S. residents today, USA Today reports
Beginning at 9 am ET, Google Glass will be available for U.S. residents for $1,500 plus tax, USA Today reports. This one-day sale is an expansion of the company's 2012 Glass Explorer program. Reference Link
April 14, 2014
16:00 EDTGILDOptions Update; April 14, 2014
iPath S&P 500 VIX Short-Term Futures down 32c to 44.41. Option volume leaders: AAPL C GILD TSLA LNG NQ BAC ZNGA according to Track Data.
14:06 EDTGOOGGoogle to acquire Titan Aerospace, WSJ says
Subscribe for More Information
13:32 EDTGOOGGoogle April volatility elevated at 68 into Q1 and revenue outlook
Subscribe for More Information
10:02 EDTVMWOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
09:09 EDTGILDGilead poised to be leader in all-oral HCV treatment, says Wells Fargo
After attending the EASL conference, Wells Fargo believes that Gilead's HCV treatment has multiple advantages over the competition. The firm keeps an Outperform rating on the stock.
09:01 EDTVMW, VMWVMware upgraded to Outperform from Underperform at CLSA
Subscribe for More Information
08:15 EDTGILDBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
07:59 EDTGILDGilead Sovaldi should take majority share of HCV market, says Stifel
Subscribe for More Information
07:45 EDTGILDAbbVie defended at BMO Capital
Subscribe for More Information
07:06 EDTVMW, GOOGU.S. Geospatial Intelligence Foundation to hold a symposium
GEOINT 2013 Symposium, originally scheduled for October 2013, is being held in Tampa, Florida on April 14-17.
06:15 EDTVMW, VMWVMware upgraded to Outperform from Underperform at CLSA
06:11 EDTINTC, GOOGIntel works with HzO to enhance water resistance in products, DigiTimes says
Subscribe for More Information
06:04 EDTINTCIntel promoting pricing strategy for tablet CPUs in China, DigiTimes reports
Intel is aggressively promoting a pricing strategy to increase sales of its tablet-use processors in China, reports DigiTimes. According to industry sources, prices of mainstream quad-core tablet CPUs have dropped to below $5 and the number of Intel-based tablets is likely to expand in proportion. Reference Link
April 13, 2014
20:11 EDTGOOGGoogle, Palo Alto, Cvent worth looking into, Barron's says
Subscribe for More Information
April 11, 2014
12:42 EDTINTCOn The Fly: Analyst Initiation Summary
ASML (ASML) initiated with a Cautious at ISI Group... Analog Devices (ADI) initiated with a Buy at ISI Group... Applied Materials (AMAT) initiated with a Strong Buy at ISI Group... Aruba Networks (ARUN) initiated with a Buy at SunTrust... Broadcom (BRCM) initiated with a Neutral at ISI Group... CSX (CSX) initiated with an Outperform at Macquarie... Cisco (CSCO) initiated with a Buy at SunTrust... F5 Networks (FFIV) initiated with a Neutral at SunTrust... Genesee & Wyoming (GWR) initiated with a Neutral at Macquarie... Intel (INTC) initiated with a Neutral at ISI Group... Juniper (JNPR) initiated with a Buy at SunTrust... KLA-Tencor (KLAC) initiated with a Neutral at ISI Group... Lam Research (LRCX) initiated with a Strong Buy at ISI Group... Linear Technology (LLTC) initiated with a Cautious at ISI Group... Maxim Integrated (MXIM) initiated with a Neutral at ISI Group... Micron (MU) initiated with a Strong Buy at ISI Group... NVIDIA (NVDA) initiated with a Neutral at ISI Group... NXP Semiconductors (NXPI) initiated with a Strong Buy at ISI Group... Qualcomm (QCOM) initiated with a Strong Buy at ISI Group... Riverbed (RVBD) initiated with a Neutral at SunTrust... SanDisk (SNDK) initiated with a Neutral at ISI Group... Teradyne (TER) initiated with a Buy at ISI Group... Texas Instruments (TXN) initiated with a Neutral at ISI Group... Trulia (TRLA) initiated with a Neutral at Susquehanna... Union Pacific (UNP) initiated with a Neutral at Macquarie... Zillow (Z) initiated with a Positive at Susquehanna... Flamel Technologies (FLML) initiated with a Buy at Roth Capital... Parker Drilling (PKD) initiated with an Accumulate at Tudor Pickering.
12:04 EDTGILDStocks with call strike movement; AMZN GILD
Amazon.com (AMZN) May 380 call option implied volatility decreased 3% to 43, Gilead (GILD) August 77 call option implied volatility decreased 15% to 45 according to IVolatility.
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:58 EDTGILDGilead valuation attractive at current levels, says RBC Capital
Subscribe for More Information
07:18 EDTINTCJefferies a buyer of Intel shares ahead of Q1 results
Subscribe for More Information
06:43 EDTGOOGGoogle enhancing Android security with apps checks, Re/code says
Subscribe for More Information
06:29 EDTGOOGGoogle says 'Jelly Bean' affected by Heartbleed
Subscribe for More Information
05:57 EDTGOOGCisco, Juniper say some products affected by Heartbleed bug, WSJ reports
Both Cisco (CSCO) and Juniper (JNPR) have disclosed that some of their products are affected by the Heartbleed bug, the Wall Street Journal reports. The companies say the security flaw affects routers, switches and firewalls used by businesses. Reference Link
05:25 EDTGILDGilead announces 95% virologic suppression in HCV study
Gilead Sciences announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi 400 mg was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease. The first study, Study GS-US-334-0125, is an ongoing open-label Phase 2 clinical trial evaluating HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin was administered for 48 weeks or to a deferred treatment arm in which this regimen was initiated after a 24-week observation period. Eighty percent of participants were treatment-experienced. Of the 22 patients who completed 24 weeks of therapy, 95% achieved virologic suppression on treatment. Additionally, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm. Sovaldi-based therapy was well tolerated in the study, and only one patient discontinued treatment due to an adverse event. The most common adverse events occurring in more than 25 percent of patients included nausea and pruritis.
April 10, 2014
16:20 EDTINTCIntel initiated with a Neutral at ISI Group
Target $26.
13:58 EDTGOOGGoogle to let any U.S. resident buy Google Glass, The Verge says
Subscribe for More Information
13:12 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
11:44 EDTGILDStocks with call strike movement; PCLN GILD
Subscribe for More Information
11:42 EDTGILDReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
10:00 EDTEMCOn The Fly: Analyst Initiation Summary
Apple (AAPL) initiated with a Buy at Deutsche Bank... Crocs (CROX) initiated with a Buy at Buckingham... Deckers Outdoor (DECK) initiated with a Buy at Buckingham... EMC (EMC) initiated with a Buy at Deutsche Bank... HP (HPQ) initiated with a Buy at Deutsche Bank... IBM (IBM) initiated with a Hold at Deutsche Bank... NeoPhotonics (NPTN) coverage resumed with a Market Perform at Raymond James... NetApp (NTAP) initiated with a Hold at Deutsche Bank... Nutrisystem (NTRI) initiated with a Buy at B. Riley... Questar (STR) initiated with an Underperform at BofA/Merrill... S&T Bancorp (STBA) initiated with an Outperform at Raymond James... STB Systems Inc (STBI) initiated with an Outperform at Raymond James... Skechers (SKX) initiated with an Underperform at Buckingham... Steven Madden (SHOO) initiated with a Buy at Buckingham... UGI Corporation (UGI) initiated with a Buy at BofA/Merrill... Web.com (WWWW) initiated with a Neutral at Buckingham... Ally Financial (ALLY) initiated with a Buy at BTIG... Visteon (VC) initiated with a Buy at Citigroup... Greatbatch (GB) initiated with a Buy at KeyBanc... Steris (STE) initiated with a Buy at KeyBanc... Cooper Companies (COO) initiated with a Hold at KeyBanc... Hill-Rom (HRC) initiated with a Hold at KeyBanc... Invacare (IVC) initiated with a Hold at KeyBanc... Teleflex (TFX) initiated with a Hold at KeyBanc... Provident Financial (PROV) initiated with a Market Perform at Keefe Bruyette... UMH Properties (UMH) initiated with a Hold at Wunderlich.
08:44 EDTEMCCLSA technology analysts hold an analyst/industry conference call
Subscribe for More Information
07:24 EDTGILDInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
06:52 EDTEMCEMC initiated with a Buy at Deutsche Bank
Subscribe for More Information
06:49 EDTGOOGMotorola Mobility names Osterloh COO
Subscribe for More Information
06:29 EDTGOOGAT&T in talks to bring ultrafast internet to North Carolina, WSJ reports
Subscribe for More Information
06:13 EDTINTCIntel to launch Haswell Refresh CPUs, 9-series chipsets in May, DigiTimes says
Subscribe for More Information
05:37 EDTGILDGilead announces Phase 2 results for investigational sofosbuvir-based regimens
Gilead Sciences announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, for the treatment of chronic hepatitis C virus, or HCV, infection. The first study, ELECTRON2, is an ongoing, open-label Phase 2 clinical trial evaluating a once-daily fixed-dose combination of SOF 400 mg and the NS5A inhibitor ledipasvir, or LDV, 90 mg, with and without ribavirin, or RBV, twice-daily, among HCV-infected patient populations. In this study, 100% of treatment-naïve genotype 3 patients receiving 12 weeks of LDV/SOF plus RBV and 64% of treatment-naïve genotype 3 patients receiving 12 weeks of LDV/SOF without RBV achieved a sustained virologic response 12 weeks after completing therapy. Among genotype 1-infected patients who had failed prior treatment with SOF plus RBV, 100% achieved SVR12 following 12 weeks of LDV/SOF plus RBV. Additionally, 65% of genotype 1-infected patients with decompensated or Child-Turcotte-Pugh Class B cirrhosis receiving 12 weeks of LDV/SOF without RBV achieved SVR12. LDV/SOF with and without RBV was well-tolerated, including among patients with more advanced liver disease. A second study, Study GS-US-342-0102, is an ongoing randomized Phase 2 clinical trial in which treatment-naïve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg or GS-5816 100 mg. In this study, 94.8% of patients receiving the 25 mg dose of GS-5816 and 96.1% of patients receiving the 100 mg dose achieved SVR12.
05:32 EDTGILDGilead announces results from study of Sovaldi
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use